Welcome. Who is here? What is this?

Here's news and info about three primary blood cancers, Lymphoma, Myeloma and Leukemia with a decided patient's perspective.  I hope this helps whether you're newly diagnosed or veteran survivor.  

       Is this You?              This is me.            We're Not Alone!    

 Is this You cancer patient    Click This is me    We are not alone, cancer warriors
Check my:Link to my blog

 

Twitter Feed

Click my Social Media, good stuff

YouTube -- https://www.youtube.com/user/JackWhelanAdvocate Twitter -- https://twitter.com/JackWhelan Google+ -- http://www.google.com/+JackWhelanAdvocate Facebook -- https://www.facebook.com/jack.whelan.98031

AACR Legislative: Write your Congressmen!

LinkedIn

Professional Research Advocacy

 

American Association for Cancer Research

 

 American Society of Clinical Oncology 

 

Alliance for Clinical Research Excellence and Safety

  

National Organization for Rare Diseases 

Rare Disease Legislative Advocates  

Research Advocacy Network 

Alliance for Clinical Trials Oncology, Jack Whelan member

Patient Advocates In

Society for Participatory Medicine

Health Advocate Code of Conduct and Professional Standards

WEGO Health Speakers Bureau 

Connect With Me At ExpertFile

 

Music and audio player

As seen or quoted on these TV stations

ABC Good Morning America CBS Sunday Morning 2 News 3 News 8 10 News 12 News WIDK 10 28 News KCOY KCAU 9 KILL TV3 KLTV 7 KMPH 26 KOTA 28 News America my FOX LIVE HD 5 blip 28 News FOX-25 FOX-5 NEWS-25HD KYTX-19 NBC4i NBC29 ABC 33-40 WAND 17HD WBAY 2 WBOC 16 WECT 6 WHBQ 13 WITN WLBT 3 WMCT 5 WRCB 3 WSET 13 WTOC 11 WTVM 9 WVUE 8

Expanded Access Programs, the critical need

http://www.cbinet.com/conference/pc15193 I'm honored to be invited to represent the experienced patient's voice and speak at this important conference about the critical need for Expanded Access in the emerging molecular level Personalized Medicine arena.

"Recent legislation, introduced just before the New Year, stands to dramatically reform the requirements of pharmaceutical and biotech manufacturers to offer compassionate use and expanded access programs. For companies whose drug is granted “Breakthrough,” “Fast Track” or “Qualified Infectious Disease Product”designation, it is critical that they understand the sweeping implications and to prepare now! Never has this meeting been more timely or critical.

The CURE Act is in the U.S. House of Representatives and intends to require that these drugs have a publicly available corporate expanded access policy for the compassionate use of the drug. This includes, but not limited to, designated point person, robust procedures, specific criteria for enrollment and policies for denials. Expect too the formation of an “Expanded Access Task Force” and upcoming formalization of the FDA’s May 2013 guidance, as the focus on Expanded Access Programs is mounting with the CURE Act".

Be the first to respond!

Leave a comment

  •